DE602004026578D1 - Neue pharmazeutische verwendungen von staurosporin-derivaten - Google Patents
Neue pharmazeutische verwendungen von staurosporin-derivatenInfo
- Publication number
- DE602004026578D1 DE602004026578D1 DE602004026578T DE602004026578T DE602004026578D1 DE 602004026578 D1 DE602004026578 D1 DE 602004026578D1 DE 602004026578 T DE602004026578 T DE 602004026578T DE 602004026578 T DE602004026578 T DE 602004026578T DE 602004026578 D1 DE602004026578 D1 DE 602004026578D1
- Authority
- DE
- Germany
- Prior art keywords
- warm
- new pharmaceutical
- pharmaceutical uses
- derivatives
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- HKSZLNNOFSGOKW-FYTWVXJKSA-N staurosporine Chemical class C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@H]1C[C@@H](NC)[C@@H](OC)[C@]4(C)O1 HKSZLNNOFSGOKW-FYTWVXJKSA-N 0.000 title abstract 2
- 241001465754 Metazoa Species 0.000 abstract 2
- 208000028185 Angioedema Diseases 0.000 abstract 1
- 206010006473 Bronchopulmonary aspergillosis Diseases 0.000 abstract 1
- 206010012434 Dermatitis allergic Diseases 0.000 abstract 1
- 206010013700 Drug hypersensitivity Diseases 0.000 abstract 1
- 208000004262 Food Hypersensitivity Diseases 0.000 abstract 1
- 206010016946 Food allergy Diseases 0.000 abstract 1
- 208000004430 Pulmonary Aspergillosis Diseases 0.000 abstract 1
- 206010039085 Rhinitis allergic Diseases 0.000 abstract 1
- 208000034972 Sudden Infant Death Diseases 0.000 abstract 1
- 206010042440 Sudden infant death syndrome Diseases 0.000 abstract 1
- 208000024780 Urticaria Diseases 0.000 abstract 1
- 201000010105 allergic rhinitis Diseases 0.000 abstract 1
- 201000008937 atopic dermatitis Diseases 0.000 abstract 1
- 208000010668 atopic eczema Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000009109 curative therapy Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 201000005311 drug allergy Diseases 0.000 abstract 1
- 235000020932 food allergy Nutrition 0.000 abstract 1
- 208000008585 mastocytosis Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 238000002638 palliative care Methods 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/16—Peri-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Child & Adolescent Psychology (AREA)
- Otolaryngology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US47957503P | 2003-06-18 | 2003-06-18 | |
PCT/EP2004/006562 WO2004112794A2 (en) | 2003-06-18 | 2004-06-17 | New pharmaceutical uses of staurosporine derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
DE602004026578D1 true DE602004026578D1 (de) | 2010-05-27 |
Family
ID=33539193
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE602004026578T Expired - Lifetime DE602004026578D1 (de) | 2003-06-18 | 2004-06-17 | Neue pharmazeutische verwendungen von staurosporin-derivaten |
Country Status (24)
Country | Link |
---|---|
US (2) | US8575146B2 (de) |
EP (1) | EP1638574B1 (de) |
JP (2) | JP5057780B2 (de) |
CN (2) | CN100457111C (de) |
AT (1) | ATE464052T1 (de) |
AU (1) | AU2004248909B2 (de) |
BE (1) | BE2017C067I2 (de) |
BR (1) | BRPI0411563B8 (de) |
CA (2) | CA2785950A1 (de) |
CY (2) | CY1110179T1 (de) |
DE (1) | DE602004026578D1 (de) |
DK (1) | DK1638574T3 (de) |
ES (1) | ES2344700T3 (de) |
FR (1) | FR17C1063I2 (de) |
HK (1) | HK1095519A1 (de) |
HU (1) | HUS000503I2 (de) |
LU (1) | LUC00055I9 (de) |
MX (1) | MXPA05013722A (de) |
NL (1) | NL300917I2 (de) |
PL (1) | PL1638574T3 (de) |
PT (1) | PT1638574E (de) |
SI (1) | SI1638574T1 (de) |
TW (1) | TWI324604B (de) |
WO (1) | WO2004112794A2 (de) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI324604B (en) * | 2003-06-18 | 2010-05-11 | Novartis Ag | New use of staurosporine derivatives |
US20060014165A1 (en) * | 2003-07-14 | 2006-01-19 | Decode Genetics Ehf. | Methods of diagnosis and treatment for asthma and other respiratory diseases based on haplotype association |
CN101693031A (zh) | 2003-11-18 | 2010-04-14 | 诺瓦提斯公司 | Kit突变形式的抑制剂 |
WO2005115385A1 (en) * | 2004-05-24 | 2005-12-08 | Ab Science | Use of c-kit inhibitors for treating acne |
EP1778224B1 (de) * | 2004-07-19 | 2014-03-26 | The Johns-Hopkins University | Flt3-inhibitoren zur immunsuppression |
MX2007001155A (es) * | 2004-07-29 | 2007-08-14 | Creabilis Therapeutics Spa | Uso de inhibidores de k-252a y de quinasa para la prevencion o el tratamiento de patologias asociadas con hmgb1. |
GB0419159D0 (en) * | 2004-08-27 | 2004-09-29 | Novartis Ag | Organic compounds |
US20080176879A1 (en) * | 2005-05-02 | 2008-07-24 | Leila Alland | Pyrimidylaminobenzamide Derivatives For Sytemic Mastocytosis |
DE602006013826D1 (de) * | 2005-07-20 | 2010-06-02 | Peter Valent | Zusammensetzungen zur behandlung von systemischer mastocytose |
CA2629478C (en) * | 2005-11-14 | 2013-10-15 | Universitat Zurich | Staurosporine derivatives for use in alveolar rhabdomyosarcoma |
WO2009092442A1 (en) * | 2008-01-23 | 2009-07-30 | Universidad De Barcelona | Treatment of portal hypertension and related conditions by combined inhibition of the vegf and pdgf signalling pathways |
EP2662078A1 (de) | 2010-11-10 | 2013-11-13 | National Jewish Health | Verfahren zur Behandlung von allergischen Zuständen |
KR20210118812A (ko) | 2018-11-01 | 2021-10-01 | 사이로스 파마수티컬스, 인크. | 시클린-의존성 키나제 7 (cdk7)의 억제제 |
US11325978B2 (en) * | 2018-11-06 | 2022-05-10 | The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Compositions and methods for treating beta-globinopathies |
US11839619B2 (en) * | 2019-09-16 | 2023-12-12 | The Regents Of The University Of California | Methods for treatment of pediatric systemic mastocytosis |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4639455A (en) * | 1984-10-02 | 1987-01-27 | Key Pharmaceuticals, Inc. | Means of aiding in the prevention of sudden infant death syndrome |
JPH0826037B2 (ja) * | 1987-01-22 | 1996-03-13 | 協和醗酵工業株式会社 | 生理活性物質k−252の誘導体 |
US5093330A (en) * | 1987-06-15 | 1992-03-03 | Ciba-Geigy Corporation | Staurosporine derivatives substituted at methylamino nitrogen |
CA2046801C (en) | 1990-08-07 | 2002-02-26 | Peter D. Davis | Substituted pyrroles |
DE69229490T2 (de) | 1991-05-09 | 2000-02-17 | Neurim Pharmaceuticals (1991) Ltd., Tel Aviv | Melatonin enthaltende Arzneimittel |
AR004480A1 (es) | 1995-04-06 | 1998-12-16 | Amico Derin C D | Compuestos de ascomicina que poseen actividad antiinflamatoria, pro cedimiento para prepararlos, uso de dichos compuestos para preparar agentesfarmaceuticos y composiciones farmaceuticas que los incluyen |
NZ333441A (en) * | 1996-06-25 | 1999-05-28 | Cephalon Inc | Use of k-252a derivatives for the treatment of peripheral or central nerve disorders, and cytokine overproduction |
US6093740A (en) | 1997-04-30 | 2000-07-25 | Eli Lilly And Company | Therapeutic treatment for skin disorders |
AU4423799A (en) * | 1998-06-04 | 1999-12-20 | Cornell Research Foundation Inc. | Methods and agents for modulating the immune response and inflammation involvingmonocyte and dendritic cell membrane proteins |
GB9903547D0 (en) * | 1999-02-16 | 1999-04-07 | Novartis Ag | Organic compounds |
AU2002227371B2 (en) | 2000-12-08 | 2007-05-10 | Ortho-Mcneil Pharmaceutical, Inc. | Macroheterocylic compounds useful as kinase inhibitors |
GB0108606D0 (en) * | 2001-04-05 | 2001-05-23 | Novartis Ag | Organic compounds |
US20030091974A1 (en) * | 2001-06-29 | 2003-05-15 | Alain Moussy | Method for screening compounds capable of depleting mast cells |
WO2003002109A2 (en) * | 2001-06-29 | 2003-01-09 | Ab Science | Use of tyrosine kinase inhibitors for treating autoimmune diseases |
CN1582150B (zh) * | 2001-10-30 | 2011-09-07 | 诺瓦提斯公司 | 作为flt3受体酪氨酸激酶活性抑制剂的星形孢菌素衍生物 |
US6998391B2 (en) | 2002-02-07 | 2006-02-14 | Supergen.Inc. | Method for treating diseases associated with abnormal kinase activity |
EP1645286A1 (de) * | 2003-04-18 | 2006-04-12 | Kyowa Hakko Kogyo Co., Ltd. | Arzneimittel zur nervenregeneration |
EP1637161A4 (de) | 2003-04-22 | 2007-06-27 | Astellas Pharma Inc | MITTEL ZUR BEHANDLUNG VON NEURODEGENERATIVEN ERKRANKUNGEN DES GEHIRNS MIT PPAR [delta] AGONIST |
TWI324604B (en) * | 2003-06-18 | 2010-05-11 | Novartis Ag | New use of staurosporine derivatives |
CN101693031A (zh) | 2003-11-18 | 2010-04-14 | 诺瓦提斯公司 | Kit突变形式的抑制剂 |
-
2004
- 2004-06-16 TW TW093117368A patent/TWI324604B/zh active
- 2004-06-17 CN CNB2004800168219A patent/CN100457111C/zh not_active Expired - Lifetime
- 2004-06-17 AU AU2004248909A patent/AU2004248909B2/en not_active Expired
- 2004-06-17 US US10/560,669 patent/US8575146B2/en active Active
- 2004-06-17 WO PCT/EP2004/006562 patent/WO2004112794A2/en active Application Filing
- 2004-06-17 DK DK04740016.3T patent/DK1638574T3/da active
- 2004-06-17 CA CA2785950A patent/CA2785950A1/en not_active Abandoned
- 2004-06-17 AT AT04740016T patent/ATE464052T1/de active
- 2004-06-17 CA CA2527703A patent/CA2527703C/en not_active Expired - Lifetime
- 2004-06-17 JP JP2006515982A patent/JP5057780B2/ja not_active Expired - Lifetime
- 2004-06-17 BR BRPI0411563A patent/BRPI0411563B8/pt not_active Application Discontinuation
- 2004-06-17 PT PT04740016T patent/PT1638574E/pt unknown
- 2004-06-17 PL PL04740016T patent/PL1638574T3/pl unknown
- 2004-06-17 EP EP04740016A patent/EP1638574B1/de not_active Expired - Lifetime
- 2004-06-17 CN CNA2007101658371A patent/CN101164539A/zh active Pending
- 2004-06-17 ES ES04740016T patent/ES2344700T3/es not_active Expired - Lifetime
- 2004-06-17 DE DE602004026578T patent/DE602004026578D1/de not_active Expired - Lifetime
- 2004-06-17 MX MXPA05013722A patent/MXPA05013722A/es active IP Right Grant
- 2004-06-17 SI SI200431450T patent/SI1638574T1/sl unknown
-
2007
- 2007-01-18 HK HK07100635.4A patent/HK1095519A1/xx not_active IP Right Cessation
-
2010
- 2010-07-06 CY CY20101100627T patent/CY1110179T1/el unknown
-
2012
- 2012-04-26 JP JP2012101493A patent/JP2012144572A/ja active Pending
-
2013
- 2013-06-27 US US13/929,438 patent/US20130289018A1/en not_active Abandoned
-
2017
- 2017-12-07 NL NL300917C patent/NL300917I2/nl unknown
- 2017-12-12 LU LU00055C patent/LUC00055I9/fr unknown
- 2017-12-14 HU HUS1700053C patent/HUS000503I2/hu unknown
- 2017-12-19 BE BE2017C067C patent/BE2017C067I2/fr unknown
- 2017-12-22 CY CY2017048C patent/CY2017048I1/el unknown
- 2017-12-28 FR FR17C1063C patent/FR17C1063I2/fr active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUS1700053I1 (hu) | Staurosporin-származékok új gyógyászati alkalmazásai | |
DK1611088T3 (da) | Hydroxymater som terapeutiske midler | |
ATE452129T1 (de) | N-phenyl-2-pyrimidine-amine derivatives | |
ATE411022T1 (de) | Pyridylpyrrol-derivate als wirksame kinase-hemmer | |
EA200970595A1 (ru) | Производные замещенных индазолов, активные в качестве ингибиторов киназ | |
EA200971053A1 (ru) | Способы лечения кожных язв | |
CY1108932T1 (el) | Ενωσεις 4-(ετεροκυκλυλ)-βενζολοσουλφοξιμινης για την θεραπευτικη αγωγη φλεγμονωδων ασθενειων | |
BRPI0410727A (pt) | composto, composição farmacêutica, e, uso de um composto | |
ATE529417T1 (de) | 3',4',5-trimethoxyflavonderivate als die schleimsekretion stimulierendes mittel, entsprechendes verfahren und pharmazeutische zusammensetzung, die diese enthält | |
BR0313718A (pt) | Composto, processo para a preparação do mesmo, composição farmacêutica, métodos para tratar um indivìduo humano ou animal sofrendo de uma condição que é mediada por cox-2 e para tratar um indivìduo humano ou animal sofrendo de um distúrbio inflamatório, e, uso de um composto | |
EA200800075A1 (ru) | Схема дозирования для празугреля | |
EA200500427A1 (ru) | Способы лечения пациентов, страдающих синдромом усталых ног или связанными с ним заболеваниями | |
NO20051936L (no) | Anvendelse av 4-pyridylmetyl-ftalazinderivater for fremstilling av et medikament for behandling av myelodysplastiske syndromer. | |
ATE412630T1 (de) | C2-disubstituierte indan-1-ol-systeme und ihre verwendung als arzneimittel | |
RU2006126471A (ru) | Способ лечения воспалительных заболеваний слюнных желез | |
TH401002069A (th) | การใช้แบบใหม่ของอนุพันธ์สเทาโรสพอรีน | |
ITMI20042187A1 (it) | Derivati isossazolici per allievare il dolore neiropatico | |
EA200900313A1 (ru) | Производные бензо[1,2,3]тиадиазина |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R065 | Request for grant of supplementary protection certificate validly filed |
Free format text: PRODUCT NAME: MIDOSTAURIN ODER EIN SALZ DAVON; REGISTRATION NO/DATE: EU/1/17/1218 20170918 Spc suppl protection certif: 122018000016 Filing date: 20180118 Expiry date: 20240618 Extension date: 20290617 |
|
R067 | Examining division decision granting supplementary protection certificate |
Free format text: PRODUCT NAME: MIDOSTAURIN ODER EIN SALZ DAVON; REGISTRATION NO/DATE: EU/1/17/1218 20170918 Spc suppl protection certif: 122018000016 Filing date: 20180118 Expiry date: 20240618 Extension date: 20290617 |
|
R069 | Supplementary protection certificate granted |
Free format text: PRODUCT NAME: MIDOSTAURIN ODER EIN SALZ DAVON; REGISTRATION NO/DATE: EU/1/17/1218 20170918 Spc suppl protection certif: 122018000016 Filing date: 20180118 Expiry date: 20240618 Extension date: 20290617 |